OVOL1: A Potential Drug Target and Biomarker (G5017)

Target Name: OVOL1

NCBI ID: G5017

OVOL1

OVOL1: A Potential Drug Target and Biomarker

The development of new drug targets and biomarkers is a critical aspect of modern medicine. OVOL1, a gene located on chromosome 16, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the science behind OVOL1 and its potential as a drug target and biomarker.

The Discovery of OVOL1

OVOL1 was first identified in 2006 by researchers at the University of California, San Diego. The gene was named after its discovery location, Oviedo, Spain. OVOL1 is a member of the POU5F1 gene family, which is responsible for the production of the protein tonin, a critical protein involved in the development and maintenance of the cytoskeleton.

Function and Importance of OVOL1

OVOL1 is a key regulator of cell division and cytoskeletal organization. It is involved in the development and maintenance of the mitotic spindle, which is a complex structure that organizes the chromosomes during cell division. In addition to its role in cytoskeletal organization, OVOL1 is also involved in the regulation of cell adhesion, migration, and invasion.

The Potential Role of OVOL1 as a Drug Target

OVOL1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for the development and progression of various diseases. One of the primary targets of OVOL1 is the regulation of cell division and cytoskeletal organization. OVOL1 plays a crucial role in the formation of the mitotic spindle, which is a critical structure that organizes the chromosomes during cell division.

In addition to its role in cell division, OVOL1 is also involved in the regulation of cell adhesion and migration. OVOL1 has been shown to play a key role in the regulation of tight junctions, which are a type of cell-cell adhesion that is critical for the regulation of cell signaling and tissue structure. OVOL1 has also been shown to be involved in the regulation of cell migration, which is critical for the development and progression of various diseases, including cancer.

OVOL1 as a Biomarker

OVOL1 has also been identified as a potential biomarker for various diseases. For example, OVOL1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases.

In addition to its potential as a biomarker, OVOL1 has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of various diseases. For example, OVOL1 has been shown to play a key role in the regulation of cell signaling and inflammation.

Conclusion

In conclusion, OVOL1 is a gene that has the potential to be a drug target and biomarker for various diseases. Its involvement in cell division, cytoskeletal organization, cell adhesion, migration, and inflammation makes it an attractive target for the development of new therapies. Further research is needed to fully understand the role of OVOL1 in the development and progression of various diseases.

Protein Name: Ovo Like Transcriptional Repressor 1

Functions: Putative transcription factor. Involved in hair formation and spermatogenesis. May function in the differentiation and/or maintenance of the urogenital system (By similarity)

The "OVOL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OVOL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets